KPRX

Kiora Pharmaceuticals Inc. (KPRX) | Rumor.io

Kiora Pharmaceuticals

KPRX

Attention (50-day avg)0%

Attention rank (50-day avg)#4,286

Bullish sentiment (50-day avg)0%

Price to earnings ratio3.66

Market capitalization11.8M

Earnings per share-2.41

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-10.8M

Social

What share of all stock conversation is about KPRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Apr 8

$KPRX has surged +19.44% to $258.00 after Perceptive Advisors and ADAR1 Capital Management announced a new financing.
The company is considering a stock split and has seen a significant increase in volume, with a 1.1M shares traded on the break of the $238.53 resistance level.
Kiora Pharmaceuticals has closed an at-the-market private placement providing up to $24M, with $5M upfront and $19M via milestone warrants exercisable at $1.94.

Generated by AI

Sentiment

Of the messages about KPRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.9% -0.2
Bearish	—	—	—	4.1% +0.2

Bullish· Apr 7

Kiora Pharmaceuticals, Inc. ($KPRX) has secured a significant commitment from Perceptive Advisors and Adar1, indicating strong investor interest.
The stock has formed a bullish pennant, suggesting a potential breakout to the upside, with a target price of $4 or higher.
The company's management changes and recent news, including a $5M investment from Perceptive Advisors and Adar1, have provided a fundamental catalyst for the stock's momentum shift.

Bearish· Jun 3

Kiora Pharmaceuticals' ($KPRX) price surge may be a "sell the news" play, according to machine learning algorithms.
Shorting $KPRX has been profitable, with multiple instances of covering short positions at higher prices, resulting in significant gains.
$KPRX has been associated with high volatility, warrant holders, and potential pump and dump schemes, making it a risky investment.

Generated by AI

Topics

Of the messages about KPRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	91.92%
Technical Analysis	—	—	0%	1.43%
Analysts	—	—	0%	6.65%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Apr 7

Kiora Pharmaceuticals, Inc. (KPRX) announced a private placement for up to $24 million, led by Perceptive Advisors, with $5 million upfront and potential for an additional $19 million through milestone-based warrant exercises.
The proceeds will support general corporate purposes, business development, and the advancement of Kiora's clinical programs, including the development of KIO-301 and KIO-104.
KPRX has four active Phase 3 trials ongoing, and its gene therapy for most types of blindness is in Phase 2, with readouts expected in Q2 2027, while its anti-inflammatory program is also in Phase 2.

Technical Analysis· Apr 7

$KPRX breaks the $2.21 level decisively, with volume surge to 24.32M confirming the move, and target is $3.33.
$KPRX breaks the $2.21 level, with volume surge to 24.41M confirming the move, and new target is $3.33.
$KPRX breaks $2.21 resistance, with volume surge to 24.03M confirming the move, and target $3.32.

Generated by AI

Community

Of the messages about KPRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	83.96%
Newcomers	—	—	0%	16.04%

Regulars· Apr 7

Kiora Pharmaceuticals has announced a private placement for up to $24 million led by Perceptive Advisors, with the company to sell 438,471 shares of common stock and issue warrants that could lead to additional gross proceeds of $19 million.
The company has $17 million in cash, no debt, a $10 million annual burn rate, and a $10 million market capitalization, with a gene therapy for most types of blindness and an anti-inflammatory treatment in phase 2 trials, with readouts expected in Q2 2027.
The stock has seen significant volume, with some users suggesting a potential price increase to $3 or more, and comparing it to a similar move by stock CYCN.

Newcomers· Apr 7

The $KPRX stock price has been increasing, with a 13% premarket surge, attributed to the company's pipeline progress and recent management changes.
Kiora Pharmaceuticals has secured a private placement for up to $24 million led by Perceptive Advisors, which may be related to the company's epilepsy asset and future data readouts for ABACUS-2 and KLARITY in 2027.
The stock has broken through the $2.21 resistance level, with a significant volume surge, and has a target price of $3.33, with a new support level to watch at $2.52.

Generated by AI

Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunitiesEncinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience

22d agoYahoo Finance

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies. Under the agreement, Kiora will receive a $1 million upfront payment and is eligible to receive development and...

1mo agoYahoo Finance

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

1mo agoYahoo Finance

Also Discussed

Investors talking about KPRX also mention

#	Name	Attention
1	Jianzhi Education Technology Group Company Limited ADRJZ	0%+0
2	Intelligent Living Application Group Inc.ILAG	0%new
3	AB Corporate Bond ETFEYEG	0%0
4	InMed Pharmaceuticals Inc.INM	0%0
5	Magic Empire Global Ltd Class A Ordinary SharesMEGL	0%0
6	Guardforce AI Co., Ltd.GFAI	0%0
7	FRZA - Forza X1, Inc.	——
8	BioAffinity Technologies Inc.BIAF	0%+0
9	MGAM - Mobile Global Esports Inc.	——
10	HPCO - Hempacco Co., Inc.	——

Kiora Pharmaceuticals Inc.

Healthcare
Biotechnology

Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other ophthalmic diseases. The company uses innovative small molecules to target pathways involved in vision loss, with programs designed to preserve, slow, or restore visual function. Its pipeline includes therapies under development for inherited retinal disorders, inflammatory eye conditions, and corneal repair applications, reflecting a specialization in diseases with limited treatment options. Kiora Pharmaceuticals Inc. works at the intersection of eye health and drug development, addressing both rare and more broadly relevant ophthalmic indications through its research and clinical programs. Headquartered in Encinitas, California, the company plays a niche role in the healthcare sector by advancing experimental therapies aimed at unmet needs in vision care.

Website

Location

332 Encinitas Boulevard

Encinitas, CA, 92024

United States

Social

What share of all stock conversation is about KPRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Apr 8

$KPRX has surged +19.44% to $258.00 after Perceptive Advisors and ADAR1 Capital Management announced a new financing.
The company is considering a stock split and has seen a significant increase in volume, with a 1.1M shares traded on the break of the $238.53 resistance level.
Kiora Pharmaceuticals has closed an at-the-market private placement providing up to $24M, with $5M upfront and $19M via milestone warrants exercisable at $1.94.

Generated by AI

Sentiment

Of the messages about KPRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.9% -0.2
Bearish	—	—	—	4.1% +0.2

Bullish· Apr 7

Kiora Pharmaceuticals, Inc. ($KPRX) has secured a significant commitment from Perceptive Advisors and Adar1, indicating strong investor interest.
The stock has formed a bullish pennant, suggesting a potential breakout to the upside, with a target price of $4 or higher.
The company's management changes and recent news, including a $5M investment from Perceptive Advisors and Adar1, have provided a fundamental catalyst for the stock's momentum shift.

Bearish· Jun 3

Kiora Pharmaceuticals' ($KPRX) price surge may be a "sell the news" play, according to machine learning algorithms.
Shorting $KPRX has been profitable, with multiple instances of covering short positions at higher prices, resulting in significant gains.
$KPRX has been associated with high volatility, warrant holders, and potential pump and dump schemes, making it a risky investment.

Generated by AI

Topics

Of the messages about KPRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	91.92%
Technical Analysis	—	—	0%	1.43%
Analysts	—	—	0%	6.65%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Apr 7

Kiora Pharmaceuticals, Inc. (KPRX) announced a private placement for up to $24 million, led by Perceptive Advisors, with $5 million upfront and potential for an additional $19 million through milestone-based warrant exercises.
The proceeds will support general corporate purposes, business development, and the advancement of Kiora's clinical programs, including the development of KIO-301 and KIO-104.
KPRX has four active Phase 3 trials ongoing, and its gene therapy for most types of blindness is in Phase 2, with readouts expected in Q2 2027, while its anti-inflammatory program is also in Phase 2.

Technical Analysis· Apr 7

$KPRX breaks the $2.21 level decisively, with volume surge to 24.32M confirming the move, and target is $3.33.
$KPRX breaks the $2.21 level, with volume surge to 24.41M confirming the move, and new target is $3.33.
$KPRX breaks $2.21 resistance, with volume surge to 24.03M confirming the move, and target $3.32.

Generated by AI

Community

Of the messages about KPRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	83.96%
Newcomers	—	—	0%	16.04%

Regulars· Apr 7

Kiora Pharmaceuticals has announced a private placement for up to $24 million led by Perceptive Advisors, with the company to sell 438,471 shares of common stock and issue warrants that could lead to additional gross proceeds of $19 million.
The company has $17 million in cash, no debt, a $10 million annual burn rate, and a $10 million market capitalization, with a gene therapy for most types of blindness and an anti-inflammatory treatment in phase 2 trials, with readouts expected in Q2 2027.
The stock has seen significant volume, with some users suggesting a potential price increase to $3 or more, and comparing it to a similar move by stock CYCN.

Newcomers· Apr 7

The $KPRX stock price has been increasing, with a 13% premarket surge, attributed to the company's pipeline progress and recent management changes.
Kiora Pharmaceuticals has secured a private placement for up to $24 million led by Perceptive Advisors, which may be related to the company's epilepsy asset and future data readouts for ABACUS-2 and KLARITY in 2027.
The stock has broken through the $2.21 resistance level, with a significant volume surge, and has a target price of $3.33, with a new support level to watch at $2.52.

Generated by AI

Kiora Pharmaceuticals

Social

Apr 8

Sentiment

Bullish· Apr 7

Bearish· Jun 3

Topics

Announcements· Apr 7

Technical Analysis· Apr 7

Community

Regulars· Apr 7

Newcomers· Apr 7

News

Kiora Pharmaceuticals names Keith Lane clinical development head

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Kiora Pharmaceuticals Inc.

Company Information

Location

News

Kiora Pharmaceuticals names Keith Lane clinical development head

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Also Discussed

Social

Apr 8

Sentiment

Bullish· Apr 7

Bearish· Jun 3

Topics

Announcements· Apr 7

Technical Analysis· Apr 7

Community

Regulars· Apr 7

Newcomers· Apr 7